The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
roche | 36129 |
roche diagnostics | 5182 |
genentech | 4435 |
roche diagnostics operations | 2160 |
roche diabetes care | 938 |
ventana medical systems | 839 |
roche molecular systems | 795 |
roche glycart | 317 |
roche palo alto | 305 |
siena biotech | 215 |
roche | 3811 |
roche diagnostics | 585 |
roche diagnostics operations | 93 |
genentech | 69 |
roche palo alto | 62 |
arius research | 33 |
roche molecular systems | 31 |
medingo | 27 |
isotechnika | 20 |
glycart biotechnology | 16 |
roche | 2873 |
genentech | 573 |
roche diabetes care | 363 |
roche diagnostics | 342 |
roche diagnostics operations | 197 |
ventana medical systems | 155 |
roche molecular systems | 131 |
roche sequencing solutions | 66 |
genia technologies | 25 |
roche glycart | 25 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
method to identify a patient with an increased likelihood of responding to an anti-canceā¦ 🛈 | 109 | 2010 |
pyrrolopyrazine kinase inhibitors | 79 | 2008 |
anti-pd-l1 antibodies and their use to enhance t-cell function | 77 | 2008 |
antibodies against human angiopoietin 2 | 75 | 2008 |
pyridin- 2 -amides useful as cb2 agonists | 69 | 2011 |
subcutaneous anti-her2 antibody formulation | 66 | 2009 |
benzoxazepin pi3k inhibitor compounds and methods of use | 65 | 2009 |
highly concentrated pharmaceutical formulations | 64 | 2009 |
novel cyclosporin analog microemulsion preconcentrates | 63 | 2001 |
antibodies binding preferentially human csf1r extracellular domain 4 and their use | 62 | 2009 |